Companies › Ryvu Therapeutics
2 active drug programs in 2 registered trials: 2 Phase 2; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| MEN1703 (SEL24, Dapolsertib hydrochloride) Dual inhibitor of PIM kinases and FLT3 | PIM1, PIM2, PIM3, FLT3 | Phase 2 | Non-Hodgkin Lymphoma, B-cell | Dec 2026 |
| RVU120 CDK8 and CDK19 inhibitor | CDK8, CDK19 | Phase 2 | Acute Myeloid Leukemia | Aug 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06534437 | MEN1703 (SEL24, Dapolsertib hydrochloride) | Phase 2 | Non-Hodgkin Lymphoma, B-cell | Oncology | Dec 2026 |
| NCT06191263 | RVU120 | Phase 2 | Acute Myeloid Leukemia | Oncology | Aug 2027 |
Criterium EpicentRx Elpiscience (Suzhou) Biopharma Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) Inhibrx Biosciences
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.